Literature DB >> 8308699

In vitro evaluation of the antimicrobial activities of selected lozenges.

R M Richards1, D K Xing.   

Abstract

The in vitro antimicrobial activities of 10 lozenges (Merothol, Merocets, Merocaine, Strepsils (two varieties), Dequacaine, Dequacets, Zensyls, Tyrozets, and Labosept) were determined by use of a microtiter counting method with Streptococcus pyogenes, Staphylococcus aureus, and Candida albicans as the test organisms. Merothol, Merocets, Merocaine, and both Strepsils formulations all reduced the counts of both S. aureus and S. pyogenes suspensions by approximately 6 log cycles within 5 and 20 min, respectively. Merothol, Merocets, and Merocaine also caused a reduction in the counts of the C. albicans suspension approximately 5 log cycles within 40 min, but no other lozenge formulation showed rapid and marked activity against C. albicans. Dequacaine and Dequacets showed marked but much slower activities against this yeast. Zensyls caused an approximately 6-log-cycle reduction in bacterial counts within 40 min, and Dequacaine, Dequacets, and Tyrozets showed marked but slower antibacterial activities. This work confirmed by a statistically sound in vitro method the in vivo antibacterial activities reported for Merothol, Merocets, and Merocaine, demonstrated equivalent antibacterial activities for Strepsils, and indicated that Merothol, Merocets, and Merocaine also showed marked activities against C. albicans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8308699     DOI: 10.1002/jps.2600821207

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  The effect of formulation on the antimicrobial activity of cetylpyridinium chloride in candy based lozenges.

Authors:  R M Richards; J Z Xing; L F Weir
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

2.  Excipient interaction with cetylpyridinium chloride activity in tablet based lozenges.

Authors:  R M Richards; J Z Xing; K M Mackay
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

3.  A multicentre, randomised, double-blind, single-dose study assessing the efficacy of AMC/DCBA Warm lozenge or AMC/DCBA Cool lozenge in the relief of acute sore throat.

Authors:  Alan G Wade; Christopher Morris; Adrian Shephard; Gordon M Crawford; Michael A Goulder
Journal:  BMC Fam Pract       Date:  2011-02-18       Impact factor: 2.497

4.  The synergy and mode of action of quercetin plus amoxicillin against amoxicillin-resistant Staphylococcus epidermidis.

Authors:  Supatcharee Siriwong; Yothin Teethaisong; Kanjana Thumanu; Benjawan Dunkhunthod; Griangsak Eumkeb
Journal:  BMC Pharmacol Toxicol       Date:  2016-08-04       Impact factor: 2.483

5.  The Effects of Allium sativum Extracts on Biofilm Formation and Activities of Six Pathogenic Bacteria.

Authors:  Zeinab Mohsenipour; Mehdi Hassanshahian
Journal:  Jundishapur J Microbiol       Date:  2015-08-25       Impact factor: 0.747

6.  Spectrum of bactericidal action of amylmetacresol/2,4-dichlorobenzyl alcohol lozenges against oropharyngeal organisms implicated in pharyngitis.

Authors:  Derek Matthews; Robert Atkinson; Adrian Shephard
Journal:  Int J Gen Med       Date:  2018-11-28

7.  Virucidal action of sore throat lozenges against respiratory viruses parainfluenza type 3 and cytomegalovirus.

Authors:  Adrian Shephard; Stela Zybeshari
Journal:  Antiviral Res       Date:  2015-09-25       Impact factor: 5.970

8.  Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes.

Authors:  Supatcharee Siriwong; Kanjana Thumanu; Tanaporn Hengpratom; Griangsak Eumkeb
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-21       Impact factor: 2.629

9.  Synergistic activity and mechanism of action of Stephania suberosa Forman extract and ampicillin combination against ampicillin-resistant Staphylococcus aureus.

Authors:  Yothin Teethaisong; Nongluk Autarkool; Kittipot Sirichaiwetchakoon; Pongrit Krubphachaya; Sajeera Kupittayanant; Griangsak Eumkeb
Journal:  J Biomed Sci       Date:  2014-09-11       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.